Loading...

PE anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104507 50 µg 122 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104508 200 µg 293 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  4. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  5. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  6. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  7. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  8. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  9. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  10. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  11. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  12. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  13. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  14. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  15. Liu M, et al. 2022. Cells. 11: . PubMed
  16. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  17. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  18. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  19. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  20. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  21. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  22. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  23. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  24. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  27. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  28. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  29. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  30. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  31. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  32. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  33. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  34. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  35. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  36. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  37. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  38. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  39. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  40. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  41. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  42. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  43. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  44. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  45. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  46. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  47. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  48. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  49. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  50. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  51. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  52. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  53. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  54. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  55. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  56. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  57. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  58. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  59. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  60. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  61. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  62. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  63. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  64. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  65. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  67. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  68. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  69. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  70. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  71. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  72. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  73. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  74. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  75. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  76. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  77. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  78. Lopes N, et al. 2022. Elife. 11:. PubMed
  79. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  80. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  81. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  82. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  83. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  84. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  85. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  86. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  87. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  88. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  89. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  90. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  91. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  92. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
RRID
AB_313110 (BioLegend Cat. No. 104507)
AB_313110 (BioLegend Cat. No. 104508)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 4    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account